



In re Application of: Kenneth W. Locke, et al.

Application No.: 10/601,862

Filed: June 24, 2003

For: Pharmaceutical compositions of isolated

orthorhombic crystalline 4-[6-acetyl-3-[3-

(4-acetyl-3-hydroxy-2-

propylphenylthio)propoxy]-2-

propylphenoxy]butyric acid and methods

of use.

Group Art Unit: 1625

Examiner: Taylor V. OH

Confirmation No.: 7180

Docket No.: 215233.00500

AMENDMENT UNDER 37 C.F.R. § 1.312


Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants are in receipt of a Notice of Allowance and Issue Fee Due Form, mailed December 13, 2005, in connection with the above-identified application. Payment of the Issue Fee, due on or before March 13, 2006, is submitted concurrently with this amendment. Pursuant to 37 C.F.R. § 1.312, the Examiner is respectfully requested to favorably consider and enter the following amendment to the present application.

Amendments to the Claims are reflected in the listing of claims which begin on page 2 of this paper.

Remarks begin on page 4.





In re Application of: Kenneth W. Locke, et al.

Application No.: 10/601,862

Filed: June 24, 2003

For: Pharmaceutical compositions of isolated

orthorhombic crystalline 4-[6-acetyl-3-[3-

(4-acetyl-3-hydroxy-2-

propylphenylthio)propoxy]-2-

propylphenoxy]butyric acid and methods

of use.

Group Art Unit: 1625

Examiner: Taylor V. OH

Confirmation No.: 7180

Docket No.: 215233.00500

AMENDMENT UNDER 37 C.F.R. § 1.312

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants are in receipt of a Notice of Allowance and Issue Fee Due Form, mailed December 13, 2005, in connection with the above-identified application. Payment of the Issue Fee, due on or before March 13, 2006, is submitted concurrently with this amendment. Pursuant to 37 C.F.R. § 1.312, the Examiner is respectfully requested to favorably consider and enter the following amendment to the present application.

Amendments to the Claims are reflected in the listing of claims which begin on page 2 of this paper.

Remarks begin on page 4.